Home > Cardiology > HFA 2022 > First non-adrenergic drug to show benefit on BP in pre-cardiogenic shock

First non-adrenergic drug to show benefit on BP in pre-cardiogenic shock

Presented By
Prof. Marco Metra, University of Brescia, Italy
Conference
HFA 2022
Trial
SEISMiC
In a pilot study, istaroxime significantly increased the systolic blood pressure (SBP) of patients with pre-cardiogenic shock. The agent was well-tolerated and was not associated with worsening arrhythmias or renal function. These results encourage further investigation of this non-adrenergic agent. “Istaroxime was designed to improve both systolic contraction and diastolic relaxation,” clarified Prof. Marco Metra (University of Brescia, Italy) [1]. The current randomised, double-blind, placebo-controlled pilot study, named SEISMiC (NCT04325035) included 60 patients with Society for Cardiovascular Angiography and Interventions (SCAI) stage B cardiogenic shock and assessed the efficacy and safety of 24-hour infusion of istaroxime in this population. The primary endpoint was the change in the Area Under Curve (AUC) for SBP over 6 hours. Patients on ist...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on